Gary Li

1.2k total citations · 1 hit paper
32 papers, 702 citations indexed

About

Gary Li is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gary Li has authored 32 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gary Li's work include Fibroblast Growth Factor Research (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Gary Li is often cited by papers focused on Fibroblast Growth Factor Research (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Gary Li collaborates with scholars based in United States, Italy and Singapore. Gary Li's co-authors include Melanie A. Krook, Julie W. Reeser, Hui‐Zi Chen, Gabrielle Ernst, Max Wilberding, Sameek Roychowdhury, Patrick Fagan, Kenneth H. Grabstein, Marcello Marelli and Maria Rosaria Esposito and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Gary Li

29 papers receiving 688 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

2020 213 citations Melanie A. Krook, Julie W. Reeser et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Li United States	13	355	197	136	128	122	32	702
Fumiaki Nakayama Japan	16	410 1.2×	206 1.0×	240 1.8×	86 0.7×	90 0.7×	30	803
Karen L. Billeci United States	9	602 1.7×	191 1.0×	225 1.7×	287 2.2×	61 0.5×	10	862
Hoa Nguyen United States	9	229 0.6×	124 0.6×	74 0.5×	77 0.6×	74 0.6×	23	490
Meng Ling Choong Singapore	14	693 2.0×	168 0.9×	97 0.7×	30 0.2×	61 0.5×	24	1.0k
Jacquin Jones United States	8	212 0.6×	449 2.3×	390 2.9×	359 2.8×	76 0.6×	10	1.1k
Jeffrey G. Kuremsky United States	9	202 0.6×	297 1.5×	55 0.4×	73 0.6×	113 0.9×	13	681
Abhijit Aithal United States	12	428 1.2×	372 1.9×	218 1.6×	115 0.9×	80 0.7×	23	809
Duosha Hu China	16	325 0.9×	317 1.6×	268 2.0×	145 1.1×	41 0.3×	19	775
Kavitha Balaji United States	9	320 0.9×	381 1.9×	229 1.7×	93 0.7×	86 0.7×	15	829
Anatol Oleksijew United States	15	634 1.8×	339 1.7×	94 0.7×	86 0.7×	30 0.2×	22	1.0k

Countries citing papers authored by Gary Li

Since Specialization

Citations

This map shows the geographic impact of Gary Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Li more than expected).

Fields of papers citing papers by Gary Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Li. The network helps show where Gary Li may publish in the future.

Co-authorship network of co-authors of Gary Li

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Li. A scholar is included among the top collaborators of Gary Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Li. Gary Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Fanching, Takeru Ehara, Steven V. Horton, et al.. (2024). Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma. Journal of Nuclear Medicine. 65(4). 586–592. 29 indexed citations

Ulaner, Gary A., et al.. (2024). Dotatate PET/CT and ²²⁵Ac-Dotatate Therapy for Somatostatin Receptor–expressing Metastatic Breast Cancer. Radiology. 312(1). e233408–e233408. 6 indexed citations

Eshaghi, Behnaz, Alex Schudel, Ilin Sadeghi, et al.. (2023). The role of engineered materials in mucosal vaccination strategies. Nature Reviews Materials. 9(1). 29–45. 18 indexed citations

Han, Guangzhou, Eunmi Hwang, Fanching Lin, et al.. (2023). Abstract 5042: Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer. Cancer Research. 83(7_Supplement). 5042–5042. 1 indexed citations

Li, Gary, Fanching Lin, Takeru Ehara, et al.. (2023). Novel peptide binder to Glypican-3 for targeted radiopharmaceutical therapy of hepatocellular carcinoma.. Journal of Clinical Oncology. 41(16_suppl). e16131–e16131. 1 indexed citations

Richardson, Samantha J., Takeru Ehara, M. Mason Guest, et al.. (2023). Novel peptide binder for EphA2-targeted radiopharmaceutical therapy for multiple solid tumors.. Journal of Clinical Oncology. 41(16_suppl). e15113–e15113.

Krishnamurthy, Nithya, et al.. (2020). Opportunities and challenges in developing tissue-agnostic anti-cancer drugs. Journal of Cancer Metastasis and Treatment. 2020. 3 indexed citations

Krook, Melanie A., Julie W. Reeser, Gabrielle Ernst, et al.. (2020). Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. British Journal of Cancer. 124(5). 880–892. 213 indexed citations breakdown →

Li, Gary, et al.. (2020). SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

10.

Pal, Sumanta K., Dean F. Bajorin, Nazlı Dizman, et al.. (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results. Cancer. 126(11). 2597–2606. 41 indexed citations

11.

Avogadri-Connors, Francesca, et al.. (2020). Abstract 2940: Molecular tumor profiling identifies actionable targets in patients with cholangiocarcinoma. Cancer Research. 80(16_Supplement). 2940–2940. 2 indexed citations

12.

Yokoyama, Yumi, Erin D. Lew, Ruth Seelige, et al.. (2019). Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor. Cancer Research. 79(8). 1996–2008. 70 indexed citations

13.

Li, Gary, Melanie A. Krook, Sameek Roychowdhury, et al.. (2019). Abstract 2206: Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors. 2206–2206. 1 indexed citations

14.

Fagan, Patrick, Colin Walsh, Danielle Murphy, et al.. (2017). Abstract 5158: Anti-tumor activity of entrectinib, a highly potent pan-TRK, ROS1 and ALK inhibitor, in molecularly defined acute myeloid leukemia. Cancer Research. 77(13_Supplement). 5158–5158. 2 indexed citations

15.

Yokoyama, Yumi, Erin D. Lew, Ruth Seelige, et al.. (2017). Abstract 4698: Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor. Cancer Research. 77(13_Supplement). 4698–4698. 1 indexed citations

16.

Stenderup, Karin, Cecilia Rosada, Kurt Shanebeck, et al.. (2015). AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use—improves psoriasis in a human xenograft transplantation model. Protein Engineering Design and Selection. 28(10). 467–480. 14 indexed citations

17.

Bariola, Pauline A., et al.. (2015). Cysteine as a Monothiol Reducing Agent to Prevent Copper-Mediated Oxidation of Interferon Beta During PEGylation by CuAAC. Bioconjugate Chemistry. 26(10). 2070–2075. 8 indexed citations

18.

Aveic, Sanja, Anke Seydel, Maria Rosaria Esposito, et al.. (2015). Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. Oncotarget. 7(5). 5646–5663. 39 indexed citations

19.

Ratnaswamy, Gayathri, Gary Li, Renuka Thirumangalathu, et al.. (2014). A Case Study of Nondelamination Glass Dissolution Resulting in Visible Particles: Implications for Neutral pH Formulations. Journal of Pharmaceutical Sciences. 103(4). 1104–1114. 16 indexed citations

20.

Todd, Christopher A., Kelli Greene, Xuesong Yu, et al.. (2011). Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. Journal of Immunological Methods. 375(1-2). 57–67. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact